# Table of Contents

**Highlights of This Issue 2009**

**REVIEW**

2011  BCL2 Inhibitors as Anticancer Drugs: A Plethora of Misleading BH3 Mimetics  
Ryan S. Soderquist and Alan Eastman

**SMALL MOLECULE THERAPEUTICS**

2018  ST-11: A New Brain-Penetrant Microtubule-Destabilizing Agent with Therapeutic Potential for Glioblastoma Multiforme  
Allison E. Cherry, Brian R. Haas, Alipi V. Naydenov, Susan Fung, Cong Xu, Katie Swinney, Michael Wagenbach, Jennifer Freeling, David A. Canton, Jonathan Coy, Eric A. Horne, Barry Rickman, Juan Jesus Vicente, John D. Scott, Rodney JY. Ho, Denny Liggitt, Linda Wordeman, and Nephil Stella

2030  BET Inhibition Induces Apoptosis in Aggressive B-Cell Lymphoma via Epigenetic Regulation of BCL-2 Family Members  

2042  CHK1 Inhibition Radiosensitizes Head and Neck Cancers to Paclitaxel-Based Chemoradiotherapy  
Holly E. Barker, Radhika Patel, Martin McLaughlin, Ulrike Schick, Shane Zaidi, Christopher M. Nutting, Katie L. Newbold, Shreerang Bhide, and Kevin J. Harrington

2055  Acridine Derivatives as Inhibitors of the IRE1α–XBP1 Pathway Are Cytotoxic to Human Multiple Myeloma  
Dadi Jiang, Arvin B. Tam, Muthuraman Alagappan, Michael P. Hay, Aparna Gupta, Margaret M. Kozak, David E. Solow-Cordero, Pek Y. Lum, Nicholas C. Denko, Amato J. Giaccia, Qunshu Zhang, Xiaoyu Yang, Steven Y. Qian, and Bin Guo

2066  A Histone Deacetylase Inhibitor, OBP-801, and Celecoxib Synergistically Inhibit the Cell Growth with Apoptosis via a DR5-Dependent Pathway in Bladder Cancer Cells  
Seijiro Toriyama, Mano Horinaka, Shusuke Yasuda, Tomoyuki Taniguchi, Yuichi Aono, Toshiya Takamura, Yukako Morioka, Tsuneharu Miki, Osamu Ukimura, and Toshiyuki Sakai

2076  αvβ3 Integrin-Targeted Radionuclide Therapy with 64Cu-cyclam-RAFT-(RGDfK) 4  
Zhao-Hui Jin, Takako Furukawa, Melissa Degardin, Aya Sugyo, Atsushi B. Tsujii, Tomoteru Yamasaki, Kazunori Kawamura, Yasuhisa Fujibayashi, Ming-Rong Zhang, Didier Botuyn, Pascal Dumy, and Tsuneo Saga

2086  Vitamin D Enhances the Efficacy of Irinotecan through miR-627–Mediated Inhibition of Intratumoral Drug Metabolism  
Meiyan Sun, Qunshu Zhang, Xiaoyu Yang, Steven Y. Qian, and Bin Guo

2096  Covalent Targeting of Fibroblast Growth Factor Receptor Inhibits Metastatic Breast Cancer  
Wells S. Brown, Li Tan, Andrew Smith, Nathanael S. Gray, and Michael K. Wendt

2107  Cotargeting HSP90 and Its Client Proteins for Treatment of Prostate Cancer  
Long Chen, Jie Li, Elia Faizah, Sukumar Sarkar, Nilah Ahmad, Sanjay Gupta, James Larner, and Xiaoqi Liu

2119  Dual and Specific Inhibition of NAMPT and PKA by KPT-9274 Decreases Kidney Cancer Growth  

**LARGE MOLECULE THERAPEUTICS**

2130  A New Class of Bifunctional Major Histocompatibility Class I Antibody Fusion Molecules to Redirect CD8 T Cells  
Martina Schmittmaegel, Eike Hoffmann, Sabine Imhof-Jung, Cornelia Fischer, Georg Drabner, Guy Georges, Christian Klein, and Hendrik Knoetgen

2143  Direct Pharmacological Inhibition of β-Catenin by RNA Interference in Tumors of Diverse Origin  

---

Downloaded from mct.aacrjournals.org on August 19, 2021. © 2016 American Association for Cancer Research.
ABOUT THE COVER

Recombinant fusion proteins of monoclonal antibodies and major histocompatibility class I complexes are potential therapeutics to increase antigenicity and facilitate elimination of tumor cells by CD8 effector T cells. This work explores novel formats to optimize potency, safety, and technical properties. For details, see the article by Schmittnaegel and colleagues beginning on page 2130.
## Molecular Cancer Therapeutics

**15 (9)**


<table>
<thead>
<tr>
<th>Updated version</th>
<th>Access the most recent version of this article at: <a href="http://mct.aacrjournals.org/content/15/9">http://mct.aacrjournals.org/content/15/9</a></th>
</tr>
</thead>
</table>

<table>
<thead>
<tr>
<th>E-mail alerts</th>
<th>Sign up to receive free email-alerts related to this article or journal.</th>
</tr>
</thead>
<tbody>
<tr>
<td>Reprints and</td>
<td>To order reprints of this article or to subscribe to the journal, contact the AACR Publications</td>
</tr>
<tr>
<td>Subscriptions</td>
<td>Department at <a href="mailto:pubs@aacr.org">pubs@aacr.org</a>.</td>
</tr>
<tr>
<td>Permissions</td>
<td>To request permission to re-use all or part of this article, use this link <a href="http://mct.aacrjournals.org/content/15/9">http://mct.aacrjournals.org/content/15/9</a>. Click on &quot;Request Permissions&quot; which will take you to the Copyright Clearance Center's (CCC) Rightslink site.</td>
</tr>
</tbody>
</table>